Merck's earnings call highlights strong operational performance in 2011, with double-digit growth in key brands and a 10% increase in non-GAAP EPS.  Management expresses optimism about 2012 despite headwinds like the SINGULAIR patent expiration and EU austerity measures.  Guidance suggests revenue will be maintained at or near 2011 levels on a constant currency basis, implying a short-term impact from foreign exchange.
[1]
